Hims & Hers Health Seen With Opportunity in Peptides -- Market Talk

Dow Jones05-13

1251 ET - Hims & Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims & Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims & Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 12, 2026 12:51 ET (16:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635467052?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635467052","market":"hk","top_or_hot":-1,"title":"Hims & Hers Health Seen With Opportunity in Peptides -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1251 ET - Hims &amp; Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims &amp; Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims &amp; Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Seen With Opportunity in Peptides -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Seen With Opportunity in Peptides -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-13 00:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1251 ET - Hims &amp; Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims &amp; Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims &amp; Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HMYY","symbol_name":"GraniteShares YieldBoost HIMS ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635467052","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635467052","pubTimestamp":1778604660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1251 ET - Hims & Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims & Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims & Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HMYY":"GraniteShares YieldBoost HIMS ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","BK4196":"保健护理服务","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIMS":"Hims & Hers Health Inc."},"translate_title":"他和她的健康与肽的机遇——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIYY":0.6,"HMYY":0.6,"HIMS":1.94,"HIMY":0.6,"HIMZ":0.6},"content_text":"1251 ET - Hims & Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims & Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims & Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. (kelly.cloonan@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 12:51 ET (16:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635467052","isCrawlerRequest":true}